$-0.13 EPS Expected for ChromaDex Corporation (CDXC)

July 14, 2018 - By Theresa Judd

ChromaDex Corporation (NASDAQ:CDXC) Logo

Analysts expect ChromaDex Corporation (NASDAQ:CDXC) to report $-0.13 EPS on August, 9.They anticipate $0.08 EPS change or 160.00 % from last quarter’s $-0.05 EPS. After having $-0.15 EPS previously, ChromaDex Corporation’s analysts see -13.33 % EPS growth. The stock decreased 2.15% or $0.1 during the last trading session, reaching $4.56. About 264,174 shares traded. ChromaDex Corporation (NASDAQ:CDXC) has risen 6.50% since July 14, 2017 and is uptrending. It has underperformed by 6.07% the S&P500.

ChromaDex Corporation, a natural products company, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company has market cap of $250.19 million. The firm offers bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; Nicotinamide riboside , a vitamin found naturally in milk for enhancing cardiovascular health, glucose levels, cognitive function, and anti-aging effects; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It currently has negative earnings. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications.

More notable recent ChromaDex Corporation (NASDAQ:CDXC) news were published by: Nasdaq.com which released: “ChromaDex added to membership of US small-cap Russell 2000® Index” on June 25, 2018, also Ocbj.com with their article: “Midday Stock Roundup” published on July 11, 2018, Globenewswire.com published: “Research Report Identifies ChromaDex, WP Carey, Rambus, Dynex Capital, Home BancShares, and Granite …” on June 19, 2018. More interesting news about ChromaDex Corporation (NASDAQ:CDXC) were released by: Nasdaq.com and their article: “TRU NIAGEN® to be featured at the American Association of Naturopathic Physicians Annual Convention and the …” published on July 09, 2018 as well as Nasdaq.com‘s news article titled: “Fourth Published Clinical Trial Confirms Long-Term Safety of NIAGEN® Supplementation at High Doses and Shows …” with publication date: July 11, 2018.

ChromaDex Corporation (NASDAQ:CDXC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.